Endometriosis Pelvic Pain and Dysmenorrhea That Did Not Respond to First-Line Combined Hormonal Contraceptives

This protocol defines the next clinical step when continuous combined hormonal contraceptive therapy — the standard first-line approach — has not achieved adequate relief of endometriosis-related pelvic pain or dysmenorrhea.

Previous Treatment — Goal Not Met

First-line empiric therapy with combined hormonal contraceptives (oral pills, transdermal patches, or vaginal rings), used continuously, with or without nonsteroidal anti-inflammatory drugs, was not sufficient.

Goal not reached: relief of endometriosis-related pelvic pain and dysmenorrhea.

Next Step — Second-Line Approach

Second-line management involves agents that act on gonadotropin-releasing hormone (GnRH) pathways. Some approaches incorporate add-back therapy to support tolerability. An alternative agent with a distinct hormonal mechanism is also among the options.

Full agent selection, supporting regimen details, duration limits, and sequencing are defined in the structured protocol below.

Clinical Goals

Improvement of dysmenorrhea and nonmenstrual pelvic pain.

Instant Access to Structured Evidence-Based Regimens

References

Second-line treatment options include gonadotropin-releasing hormone (GnRH) receptor agonists with add-back therapy, GnRH receptor antagonists, and danazol.
They improve dysmenorrhea and nonmenstrual pelvic pain and allow for titration to balance effectiveness and tolerability.

View source ↗